FIGURE 4.

(a) VDZ infusion frequency every 4–6 weeks versus every 8 weeks in patients with CD in anti‐TNF‐experienced and anti‐TNF‐naive patients at time intervals T1 (Months 4–8) and T2 (Months 12–16). Every 4–6 weeks: n = 17/82, 17/60, 3/46 and 7/40; every 8 weeks: n = 65/82, 43/60, 43/46 and 33/40 for anti‐TNF‐experienced and anti‐TNF‐naive patients at T1 and T2, respectively; *p < 0.05). (b) VDZ infusion frequency every 4–6 weeks versus every 8 weeks in patients with UC in anti‐TNF‐experienced and anti‐TNF‐naive patients at time intervals T1 (Months 4–8) and T2 (Months 12–16). Every 4–6 weeks: n = 9/59, 10/37, 7/58 and 9/46; every 8 weeks: n = 50/59, 27/37, 51/58 and 37/46 for anti‐TNF‐experienced and anti‐TNF‐naive patients at T1 and T2, respectively. CD, Crohn's disease; TNF, tumour necrosis factor; UC, ulcerative colitis; VDZ, vedolizumab